ArticleBMC pediatrics2021

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.

Masaaki Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.